The FDA has approved nemolizumab (Nemluvio) for moderate-to-severe atopic dermatitis in patients aged 12 years and older. Nemolizumab targets the IL-31 receptor, known to promote itching and inflammation in atopic dermatitis. Clinical trials showed significant improvement in patients taking nemolizumab compared to placebo, with improved skin condition and reduced itching. Safety profiles were similar between the treatment and placebo groups, with common adverse reactions being headache, arthralgia, urticaria, and myalgia. No deaths were reported. Nemolizumab is also being reviewed for prurigo nodularis treatment in multiple countries. The trials were funded by Galderma, the manufacturer.
Source link
Nemolizumab Gets FDA Nod for Atopic Dermatitis
